(Q33935441)

30 July 2017

title

Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem (English)

1 reference

30 July 2017

1 reference

1 reference

1

Sujata M Bhavnani

1 reference

30 July 2017

2

Jeffrey P Hammel

1 reference

30 July 2017

5

Paul G Ambrose

1 reference

30 July 2017

Brenda B Cirincione

3

1 reference

30 July 2017

Matthew A Wikler

series ordinal

4

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 September 2005

1 reference

Antimicrobial Agents and Chemotherapy

30 July 2017

published in

1 reference

30 July 2017

volume

49

1 reference

30 July 2017

issue

9

1 reference

30 July 2017

page(s)

3944-3947

1 reference

Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential

30 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1195437

In vitro antimicrobial activity of doripenem, a new carbapenem

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1195437

Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1195437

Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1195437

10.1128/AAC.49.9.3944-3947.2005

5 July 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference

30 July 2017

1 reference